Telix Pharmaceuticals announced the establishment of Telix Japan, along with the appointment of the first two members of the Japanese leadership team.

Telix Japan is wholly-owned operating subsidiary of Telix Pharmaceuticals. The purpose of the subsidiary is to support Telix’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan. Dr. Shintaro Nishimura has been appointed as president and chief operating officer, and Dr. Takeshi Oka will take on the role of chief medical officer.

Telix co-founder and chief executive officer Dr. Christian Behrenbruch said, “Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies. The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”